Role of Yacrujjay tablet in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

A Randomized, Open labelled Controlled Clinical Trial to Evaluate the Effect of Yacrujjay in Non-Alcoholic Fatty Liver Disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/047884

Enrollment

Registered

2022-12-05

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Non-alcoholic fatty liver disease patient Diagnosed by abdomen ultrasonic examination. Or Fibroscan a. Non-drinker (Alcohol intake per week: female-under 140g, male- under 210g) Or total abstainer or with alcohol intake of less than 20g/ day for female and less than 30 g/day for males. 2.Both diagnosed and newly diagnose patients of NAFLD will be included 3.Subjective Criteria (Ajirna, Aruchi, Atilalastrava, Chardi, Aadhmana, Vibhandha)

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating females. 2.Alcoholic Fatty Liver Disease Chronic Smoker, drug abusers, will be excluded from study 3.Chronic illness like tuberculosis, acute hepatitis and other life-threatening conditions

Design outcomes

Primary

Measure	Time frame
1.fatty liver changes in USG between the groups (Pre and Post) 2.Monthly Changes in NAFLD Symptoms over the 4 months of study treatment between the groupsTimepoint: Day 0 Day 30 Day 60 Day 90 Day 120	—

Secondary

Measure	Time frame
1. Monthly Changes in Body Mass index 2. Changes in Fib 4 Index, NAFLD Fibrosis Score, LFT, CBC ,Lipid Profile And FibroscanTimepoint: Day 0 Day 30 Day 60 Day 90 Day 120	—

Countries

India

Contacts

Public ContactDr Dhaval Dave

Parul Institute of Ayurveda

drprakash.kc@gmail.com9916204070

Outcome results